NCT07143734 Transcranial Pulse Stimulation for Alzheimer's Disease
| NCT ID | NCT07143734 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Chinese University of Hong Kong |
| Condition | Alzheimer Dementia (AD) |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2025-07-21 |
| Primary Completion | 2026-04 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 40 participants in total. It began in 2025-07-21 with a primary completion date of 2026-04.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
TPS is a non-invasive therapeutic modality that uses focused, low-energy pulse stimulation to stimulate tissue regeneration and reduce inflammation. In the context of neurological disorders, it is hypothesized that TPS can modulate neuronal activity, enhance synaptic plasticity, and reduce neuroinflammation. It is a relatively new application in neurological disease treatment and is still under intense investigation.
Eligibility Criteria
Inclusion Criteria: * Adults who have been clinically diagnosed with Alzheimer's Disease in the early stage 2-6a according to the Functional Assessment Staging Test (In Appendix A) * The mental capacity to give informed consent for research is made by an experienced geriatrician based on Appendix A. * Aged 60-90 years old. * Able to make informed consent under assistance, which is witnessed and signed by a family caregiver. Exclusion Criteria: * Cannot understand Chinese. * Mentally incapacitated, unable to provide informed consent * Inability to remain still for 30 minutes * Lack of available family caregiver to answer questionnaires * Alcohol or substance dependence * Major neurological conditions, including: * Brain tumor * Brain aneurysm * Presence of any metal implants in the brain * Hemophilia or other blood clotting disorders * History of thrombosis
Contact & Investigator
Timothy Chi Yui Kwok, PhD
PRINCIPAL INVESTIGATOR
Department of Medicine & Therapeutics, Faculty of Medicine, The Chinese UNiversity of Hong Kong
Frequently Asked Questions
Who can join the NCT07143734 clinical trial?
This trial is open to participants of all sexes, aged 60 Years or older, up to 90 Years, studying Alzheimer Dementia (AD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07143734 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07143734 currently recruiting?
Yes, NCT07143734 is actively recruiting participants. Contact the research team at sumkichu2015@link.cuhk.edu.hk for enrollment information.
Where is the NCT07143734 trial being conducted?
This trial is being conducted at Hong Kong, Hong Kong.
Who is sponsoring the NCT07143734 clinical trial?
NCT07143734 is sponsored by Chinese University of Hong Kong. The principal investigator is Timothy Chi Yui Kwok, PhD at Department of Medicine & Therapeutics, Faculty of Medicine, The Chinese UNiversity of Hong Kong. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.